$PTN on NYSE AMERICAN
February 28, 2024
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
February 15, 2024
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
February 09, 2024
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
February 05, 2024
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
February 01, 2024
Palatin Announces Closing of $10 Million Registered Direct Offering
January 30, 2024
Palatin Announces $10 Million Registered Direct Offering
January 08, 2024
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
December 20, 2023
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
December 18, 2023
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
November 14, 2023
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
November 09, 2023
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
October 24, 2023
Palatin Announces Closing of $5 Million Registered Direct Offering
October 23, 2023
Palatin Announces $5 Million Registered Direct Offering
October 19, 2023
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
October 18, 2023
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
October 16, 2023
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
October 13, 2023
Palatin Receives Notice of Non-Compliance from NYSE American
September 28, 2023
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
September 22, 2023
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
September 07, 2023
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
August 10, 2023
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
August 08, 2023
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
August 07, 2023
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®
August 04, 2023
Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
July 11, 2023
Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results
May 30, 2023
Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
May 16, 2023
Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
May 11, 2023
Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023
May 09, 2023
Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference
May 08, 2023
Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar
May 01, 2023
Palatin Technologies to Host Key Opinion Leader Webinar
April 27, 2023
Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference
April 25, 2023
Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma
April 19, 2023
Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results
April 18, 2023
Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences
March 02, 2023
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease
February 28, 2023
Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
February 15, 2023
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
February 10, 2023
Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
January 19, 2023
Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
January 18, 2023
Palatin Receives $4.7 Million of Non-Dilutive Funding
January 10, 2023
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
January 05, 2023
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
November 14, 2022
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
November 09, 2022
Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
October 31, 2022
Palatin Announces $10 Million Registered Direct Offering
October 24, 2022
Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting
October 20, 2022
First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial
October 17, 2022
Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)
- No Recent Filings Found.
